| Autor: |
Voicu V; Swiss Federal Institute of Technology Zurich (ETHZ), Switzerland.; drugsafety.ch, 8700 Küsnacht ZH, Switzerland., Diehm N; Center for Vascular Medicine, 5000, Aarau, Switzerland., Moarof I; Cardiology Center Mittelland, 5001, Aarau, Switzerland., Parejo S; Medical Genetics Laboratory, Labor Risch, 3097, Berne-Liebefeld, Switzerland., Badiqué F; Medical Genetics Laboratory, Labor Risch, 3097, Berne-Liebefeld, Switzerland., Burden A; Swiss Federal Institute of Technology Zurich (ETHZ), Switzerland., Niedrig D; drugsafety.ch, 8700 Küsnacht ZH, Switzerland.; Hospital Pharmacy, Clinic Hirslanden Zurich, 8032, Zurich, Switzerland., Béchir M; Center for Internal Medicine, Hirslanden Clinic Aarau, 5001 Aarau, Switzerland., Russmann S; Swiss Federal Institute of Technology Zurich (ETHZ), Switzerland.; drugsafety.ch, 8700 Küsnacht ZH, Switzerland.; Center for Internal Medicine, Hirslanden Clinic Aarau, 5001 Aarau, Switzerland.; University of Nicosia Medical School, 2408, Nicosia-Egkomi, Cyprus. |
| Abstrakt: |
Aim: Implementation of CYP2C19 point-of-care (POC) pharmacogenetic (PGx) testing with personalized treatment recommendations. Methods: POC CYP2C19 genotyping plus expert evaluation of risk factors for ischemic and bleeding events. Results: 167 patients underwent PGx testing, 54 (32.3%) were CYP2C19 loss of function carriers, and POC versus standard PGx analysis results for *2 and *3 variants matched in 100%. Antiplatelet therapy was adjusted in 44 patients (26.3%), but always required consideration of patient-specific factors. Conclusion: CYP2C19 POC-PGx is reliable and offers clinically relevant advantages for immediate evidence-based adaptations of antiplatelet therapy, whereas in less acute cases conventional PGx testing can also have advantages. Antiplatelet therapy has become more complex, and implementation of PGx-based personalized antiplatelet therapy requires complementary expert knowledge. |
